Abstracts

DISCOVERY AND CHARACTERIZATION OF A VIRUS-INTRINSIC HIV LATENCY CIRCUIT

Over the past decade, our studies found that HIV-1 latency is driven by stochastic fluctuations in Tat transcription (Weinberger et al. Cell 2005), which provided the first evidence for a classic theory that transcriptional fluctuations (a.k.a., ‘noise’) are harnessed for cell-fate decisions. We subsequently characterized a ‘hardwired’ virus-intrinsic HIV circuit that regulates latency and appears…

SILENCING OF RETROVIRAL GENE EXPRESSION BY THE HUSH COMPLEX

Retroviral DNAs are transcriptionally silenced in a number of settings and in specific cell types, an important mechanism for the inhibition of virus replication. The HUSH complex (containing the three subunits TASOR/FAM208A, MPP8, and periphilin) was originally identified as required for the maintenance of silencing of transfected DNAs integrated into heterochromatic regions of vertebrate genomes.…

THE POWER OF THE HIV PROMOTER: IMPACT OF HIV-DRIVEN VIRAL AND HOST GENE EXPRESSION

Antiretroviral therapy (ART) inhibits the enzymatic function of viral proteins or blocks viral entry but does not inhibit HIV-1 LTR promoter activity. The HIV-1 LTR remains functional and active despite effective ART. Around 1–64 per million CD4+ T cells contain replication-competent HIV-1 proviruses. HIV-1 LTR drives the expression of intact HIV-1 proviruses, leading to viral…

DYNAMICS OF ACUTE HCV IN WESTERN EUROPE

The Global Health Sector Strategy GHSS calls for the elimination of viral hepatitis as a public health threat by 2030 (reducing new infections by 90% and mortality by 65%). Indeed, with the advent of highly successful and well tolerated direct acting antiviral combinations, allowing HCV cure after short durations of treatment within 8-12 weeks in…

A VACCINE TO PREVENT HCV: ARE WE GETTING THERE?

The World Health Organization set goals in 2016 for reductions in prevalent and incident hepatitis C infection necessary to achieve elimination of HCV as a public health problem by 2030. Modeling demonstrates that global HCV control will require annual rates of cure that are consistently and significantly higher than new HCV infection rates. However, a…

THE STORY OF U=U: SCIENTIFIC UNDERPINNINGS

The story of U=U began in the 1990s when it became apparent that the risk of sexual transmission of HIV varied by sexual practice. In the beginning of this century, many physicians started to question if there was in fact any risk of HIV transmission at all during fully suppressive antiretroviral therapy. The Rakai data…

CARING FOR U: CLINICAL CONUNDRUMS

U=U, the concept that a person with an undetectable viral load is incapable of transmitting HIV sexually, has transformed the lives of people living with HIV worldwide and is doing much to reduce the stigma associated with this condition (although there is still a long way to go). Evidence for U=U comes from clinical trials…

ME AND U: COMMUNITY PERSPECTIVES

In early 2016, the Undetectable=Untransmissable (U=U) campaign began in an effort to ensure the message of U=U was shared with community; at the time there was much resistance to the science and hesitance to share the message with providers and people living with HIV. Led by people living with HIV, the campaign took off and…